Jared Kelly
Patrimonio netto: 118 612 $ in data 31/05/2026
Patrimonio netto: 118 612 $ in data 31/05/2026
Jared Kelly is currently Chief Executive Officer & Director at Oncolytics Biotech, Inc. since 2025.
Mr. Kelly is also Secretary, Senior Vice President & General Counsel at Ambrx Biopharma Cayman, Inc. since 2023.
Formerly, Mr. Kelly was a Partner at Lowenstein Sandler LLP.
Mr. Kelly completed graduate studies at Georgetown University Law Center.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/06/2026 | 114.050 ( 0,1% ) | 118 612 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Amministratore Delegato | 11/06/2025 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Consigliere Generale | 13/09/2023 |
| Società | Posizione | Fine |
|---|---|---|
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Georgetown University Law Center
Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale